Andrea Mazur
Corneal and Contact Management · Margate City, NJNPI 1730180670
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 28.5% of the total. Reporting peaked in 2023 at $565 and has fallen 94.3% since, to $32 in 2025.
Across 75 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$460
- Alcon$343
- Bausch & Lomb Americas Inc.$254
- AbbVie$174
- Oyster Point Pharma, Inc.$159
- Novartis$93
- plus $133 from 5 others
What the payments were for
- Food & beverage$1,59799%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 22 | $460 |
| Alcon | 9 | $343 |
| Bausch & Lomb Americas Inc. | 12 | $254 |
| AbbVie(2 entities) | 5 | $174 |
| Oyster Point Pharma, Inc. | 12 | $159 |
| Novartis | 7 | $93 |
| Johnson & Johnson Vision Care, Inc. | 2 | $47 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $40 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,615 in reported general payments places this provider in the 60th percentile of 45 corneal and contact management providers in New Jersey.
See all corneal and contact management providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 26 | $38,713 |
| XiidraLifitegrast | 12 | $19,944 |
| LumiganBimatoprost | 29 | $10,238 |
| Travoprost | 18 | $4,579 |
| Bepotastine Besilate | 13 | $2,681 |
| Loteprednol Etabonate | 20 | $2,323 |
| Azelastine Hcl | 77 | $2,189 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 29 | $1,221 |
| Latanoprost | 82 | $916 |
| Prednisolone Acetate | 22 | $616 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $439 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 43 | $398 |
| ErythromycinErythromycin Base | 15 | $146 |
| MoxifloxacinMoxifloxacin Hcl | 15 | $141 |
| Timolol Maleate | 20 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $174 | $48,95155 claims |
| Bausch & Lomb Americas Inc.Xiidra | $254 | $19,94412 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $40 | $2,32320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 45 corneal and contact management providers in New Jersey.
Other corneal and contact management in Margate City
- Bradford RippsLake Hopatcong$94K
- Vittorio MenaFairview$53K
- Kenneth DanielsLambertville$14K
- Thomas ConroyBloomfield$9K
- Alan SchlusselWest Orange$8K
- Danica YangCranford$7K
- Daniel IsaacCherry Hill$5K
- Amy SteinParamus$4K
- Paul DifioreMount Laurel$3K
- Jeffrey CaseFreehold$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.